Skip to main
TVGN
TVGN logo

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings Inc. has demonstrated a strong potential for its investigational therapy, TVGN 489, in recent clinical trials, showcasing rapid viral elimination and sustained immune cell persistence along with an excellent safety profile. The therapy notably produced faster and more consistent symptom resolution in high-risk patients, including a significant portion of immunocompromised individuals, when compared to standard care. These positive clinical outcomes emphasize the efficacy of Tevogen's unique ExacTcell platform in treating infectious diseases, which may contribute to a favorable long-term outlook for the company.

Bears say

Tevogen Bio Holdings faces a challenging landscape due to the limitations of traditional immunotherapy approaches that focus on single viral proteins, especially in the context of rapidly mutating viruses and emerging variants like XFG. This indicates a potential gap in their therapeutic efficacy, which could hinder the company's ability to compete in a dynamic market. Furthermore, the reliance on a narrow treatment strategy raises concerns regarding the long-term sustainability and commercial viability of Tevogen’s product pipeline.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.